\
&
Contact us
\
&
Contact us
Published on | 5 years ago
ProgrammesSince the start of European Research Council (ERC) in 2007 a lot of investigator-driven frontier research across all fields has been funded. The celebration of the 10.000th ERC grantee today provides an opportunity to look at what the impact of ERC funded research has been. Fifteen projects are highlighted which have contributed to scientific research and to the European research landscape over the years. One of these projects is the ERC Synergy grant funded under the 2013 call “Imbalance-P - Effects of phosphorus limitations on Life, Earth system and Society”. Synergy grant projects consist of minimum two tot maximum four Principal Investigators and their teams that collaborate to address ambitious research problems. Biogeochemist and professor Ivan Janssens from the University of Antwerp is involved in Imbalance-P. A story and podcast on this project which is “bringing the impact of nutrient imbalance to global attention” can be consulted via the ERC website
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
